Dr. Ursa A. Brown-Glaberman
Claim this profileUniversity of New Mexico Cancer Center
Studies Breast Cancer
Studies Parotid Gland Cancer
20 reported clinical trials
45 drugs studied
About Ursa A. Brown-Glaberman
Education:
- Earned an MD (Doctor of Medicine) from an unspecified institution.
Experience:
- Serves as an Associate Professor in the Department of Internal Medicine, Division of Hematology/Oncology, at the UNM School of Medicine.
- Holds the position of Medical Director for Clinical Research at the University of New Mexico Comprehensive Cancer Center (UNMCCC).
- Specializes in the treatment of breast and gastrointestinal cancers.
- Awarded the National Cancer Institute's Cancer Clinical Investigator Team Leadership Award in 2017.
- Leads both the Breast and Gastrointestinal Cancer Programs at UNMCCC.
Area of expertise
1Breast Cancer
Stage IV
HER2 negative
Stage III
2Parotid Gland Cancer
Stage IV
HER2 positive
HER2 negative
Affiliated Hospitals
Clinical Trials Ursa A. Brown-Glaberman is currently running
Marker-Directed Monitoring
for Breast Cancer
This trial studies if using blood tests to decide when to do scans is as effective as the standard way for monitoring patients with a specific type of breast cancer that has spread. The blood tests act like an early warning system for cancer activity.
Recruiting1 award N/A
Pembrolizumab
for Triple-Negative Breast Cancer
The phase III trial compares the effect of pembrolizumab to observation for the treatment of patients with early-stage triple-negative breast cancer who achieved a pathologic complete response after preoperative chemotherapy in combination with pembrolizumab. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. This trial may help researchers determine if observation will result in the same risk of cancer coming back as pembrolizumab after surgery in triple-negative breast cancer patients who achieve pathologic complete response after preoperative chemotherapy with pembrolizumab.
Recruiting2 awards Phase 319 criteria
More about Ursa A. Brown-Glaberman
Clinical Trial Related5 years of experience running clinical trials · Led 20 trials as a Principal Investigator · 6 Active Clinical TrialsTreatments Ursa A. Brown-Glaberman has experience with
- Cisplatin
- Pembrolizumab
- Palbociclib
- Fluorouracil
- Gemcitabine
- Gemcitabine Hydrochloride
Breakdown of trials Ursa A. Brown-Glaberman has run
Breast Cancer
Parotid Gland Cancer
Gallbladder Cancer
Bile Duct Cancer
Breast cancer
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
What does Ursa A. Brown-Glaberman specialize in?
Is Ursa A. Brown-Glaberman currently recruiting for clinical trials?
Are there any treatments that Ursa A. Brown-Glaberman has studied deeply?
What is the best way to schedule an appointment with Ursa A. Brown-Glaberman?
What is the office address of Ursa A. Brown-Glaberman?
Is there any support for travel costs?
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.